Roche Pharmaceutical Development and Sales Overview
Polivy (polatuzumab vedotin, RG7596)
ADC targeting CD79b to treat B cell malignancies
Indication
Phase/study
# of patients
Design
☐
Primary endpoint
■
Status
CT Identifier
In collaboration with Seagen Inc.
"
1L DLBCL
Phase III
POLARIX
N=879
"
ARM A: Polivy plus R-CHP
ARM B: R-CHOP
Progression-free survival
FPI Q4 2017
Recruitment completed Q2 2019
Study met primary endpoint Q3 2021
Data presented at ASH 2021
Filed in EU, Japan and China Q4 2021
Published in NEJM 2022 Jan 27;386(4):351-363
"
Approved in EU Q2 2022
☐
Filed in US Q3 2022
NCT03274492
DLBCL-diffuse large B cell lymphoma; R-CHP-Rituxan, cyclophosphamide, hydroxydoxorubicin, prednisone; R-CHOP-Rituxan, cyclophosphamide, doxorubicin, vincristine, and prednisone; ASH-American Society of Hematology,
NEJM-New England Journal of Medicine
Roche
78
OncologyView entire presentation